Skip to main content
KMTS $27.88 -0.34%
KMTS logo
KMTS · Kestra Medical Technologies, Ltd.
Track KMTS — free
$27.88 -0.10 (-0.34%) Play latest call Q4 2026 earnings call transcript
Market Cap
$1.67B
Shares
59.56M
Volume · Nov 17 73.07K Avg daily vol (3M) 410.37K
All webcasts

Conference · 2026-11-10

Kestra Medical Technologies, Ltd. (KMTS) November 10, 2026 Conference Transcript

Concluded Nov 10, 2026 Audio replay
Nov 10, 2026 32:44 37 turns
Period
2026-11-10
Runtime
32:44
Sources
2 artifacts

Transcript & audio

32:44 Audio
Mike Pollark Analyst — Wolf Research, LLC

Good afternoon. Welcome to the Wolf Healthcare Conference. My name is Mike Polark, Medical Device Analyst here at Wolf Research. Pleased in this session to be joined by Kestra Medical, CEO Brian Webster, CFO Vaseem Maboub. Brian and Vaseem, welcome. Thanks for being here. Thanks for having us. Brian, I'll pass it to you to set the stage, and then we can jump into some Q&A. Maybe reflect on the last 18, Kestra's been public for about 18 months, called a year and a half, almost two years. Just reflect on those couple years of the journey. Kestra's obviously been a much longer journey, but you're in growth mode, you're in execution mode. What stands out? What are you most proud of? And what excites you about the road ahead?

Yeah, well, I appreciate the question, and Mike, thanks for having us here today. I think it's been quite a journey over the last 18 months. We went from sort of the shock treatment of trying to take a private company public and all the things that have to happen to do that effectively, all the process development, people development, all those things. We're kind of on, I think, mostly on the other side of that now. So those are becoming more a part of our normal cadence and our normal day. I think, you know, there's a couple of things that we're really excited about. One, you know, you've seen the steady execution coming from the company, and I think we really like to have a high say-do ratio. You know, when we say we're going to do something, we like to really be good at following through and doing that, and I think so far we've been doing that, and that's because we've got just an amazing team. You know, we're excited about the market. The market is growing. I'm sure we'll talk about that. But, you know, the more we get into the category and we understand the different patient needs and clinical needs, the more problems that we think we can solve. And ultimately, when you're a company that has a really strong engineering and clinical capability, that's what you're looking for. You're looking for problems to solve. And so I think we, across the company, are just really excited about solving more issues in the future and adding to our platforms and continuing to just drive what's a really exciting growth engine into the future.

Mike Pollark Analyst — Wolf Research, LLC

Good setting of the stage. I will ask about the WCD market. I think we see Kestra's numbers. The growth rates are high. It's very clear you're taking care. But the incumbent here has a very large business, and they've talked more constructively about their WCD performance. I view this glass half full. It's good to see that it validates the market opportunity, which is described as very large, despite the incumbent having product in the market for two decades. So I think it's very healthy. My question to you is, Why? What are the one, two, or three things that you think are creating space for you to have great success and also helping, you know, that might also be helping their performance?

Yeah, yeah. Well, I think... I think first and foremost, you have to accept the fact that we came into the market and we solved a problem that was there. You know, the reason that they're, that market, which I consider the kind of the classical WCD market to be the post-MI patient, the usually guy who's been revascularized, he's probably going to be a candidate for an implantable device in 45 or 90 days. And the issue that we solved was wearability, was the false alarm issue, was all the gender specificity issue, all the things that were preventing that market from growing, we solved. And so we're seeing that unfold. So that's one reason why you're seeing the strong growth. I think any time you get a second company coming into a monopoly market, I think in MedTech we've seen lots of cases like that where having somebody echoing the messaging around the need for that category always drives market growth, so that's pretty well established. Both companies, Kestra, you know, we published, about a year ago, we published our ACE-PASS, which is our FDA post-approval study data, 21,000 patients, and. Among the things that that study demonstrated was that the risk level for these patients was higher than most of the clinicians really appreciated, and in particular with the heart failure patients. And so, we've been out there really beating the drums about that issue, and consequently, you know, we're seeing more prescribers who are prescribing that maybe weren't prescribing to the broader range of their patients than they have before. Zoll also published a large study, a German registry study, that essentially showed the same thing. And so they're out selling the same message. And so when you have two companies with 40,000 patients' worth of data echoing the same messaging around that category, that's what leads to market growth. And on top of all those things, we're doing some really exciting stuff when it comes to medical education. We've had some really highly successful APP education programs recently in different locations around the country. I think it's a combination of all those things. And by our math, with the Zoll recent earnings release and our own, you know, we see the market the last 12 months. It's grown at 14%, and that's pretty healthy for a billion-dollar-plus category, so we're pretty excited about that.

Mike Pollark Analyst — Wolf Research, LLC

Do you have hard evidence to suggest that heart failure is growing faster than post-MI, or do you believe both slices of tam?

Definitely. It's definitely growing faster than post-MI. The population itself of patients who are experiencing heart failure is definitely growing faster, but we see in our own data that that patient population is growing faster than the post-MI patients. The nice thing for us, of course, in our model, in the rental model, is those heart failure patients are also longer wear patients, and longer wear has better economics attached to that. So, you know, we're helping to solve a problem for that patient population, but that also is attractive economically.

Mike Pollark Analyst — Wolf Research, LLC

On the prescriber comment, so existing prescribers prescribing more broadly. What about in the last year as market growth has perked up? What can you discern about new prescribers engaging with this product? Is it mostly the same-store growth, or are there new stores, new prescribers that is meaningful?

I think our view is it's probably, you know, 75% of it's same-store growth, and a quarter of it is new prescribers. There's definitely new prescribers that are seeing this, especially what we're seeing is in some of our fellows programs where we're trying to really do some education with fellows. They really are attracted to newer technologies, you know, updated, modern technologies, and they look at our kind of a device, and they look at it and say, hey, there's more utility to this than just a standard shock box like they've been used to with a competitive device, and so they're looking at it as another tool that they can use to help manage these patients, and so that's been one of the drivers in some of those prescriber populations.

Mike Pollark Analyst — Wolf Research, LLC

I'll ask on the guidelines. Heart failure in the U.S. still doesn't have guideline support, but between SCD Protect and ACE-PAZ, there's a substantial amount of new data, and I believe mostly that data is focused on this heart failure patient population. If I have it correct, the guidelines for WCD were last adjusted in 2017, 10 years ago. What needs to happen next for some credit in the guidelines? Is there an identifiable pathway review timeline? Is this enough data, you think, to sway the guidelines, these two large studies, or is something more needed?

Well, first, I think we all know that the guidelines process is not a well-defined start and stop process, and, you know, essentially, there has to be enough data that would cause that subcommittee that's looking, in this case, at the arrhythmia guidelines for them to reconvene, reassess all that data, and then make decisions about whether to adjust the guidelines from today. What is mostly a 2B indication up to a 2A indication. We don't believe that a randomized trial is in order here, and none of our clinical advisors would support that because there's not an IRB that would approve it for ethical reasons, because the standard is out there with the WCD protection.

Mike Pollark Analyst — Wolf Research, LLC

Getting randomized to nothing.

Yeah, yeah, yeah. If you tried to redo the VEST trial, which was Zoll's randomized trial, which was randomized to a WCD on one hand or nothing on the other, nobody's going to do the nothing on the other, and there would be no benefit in doing a head-to-head at this point because it would take so many patients to prove that given the cardiac arrest rate. So I think we believe that we can add more outcomes data to our data set from the ACE-PASS data by going and getting the outcome data for that patient population. We think that's the missing link. And all the other data that needs to be there is probably there. In fact, recently, there was an HRS expert committee that convened and published a paper where they indicated... A strong, really strong recommendation for the use of WCDs in some of these patient populations, including the ischemic cardiomyopathy patients, the heart failure patients. So that's good that that happened sort of independently, and that just layers on top. And I think when we continue to add some additional information, then I think it's pretty reasonable that that group will reconvene. And what they will assess is a lot more data than. When they assessed in 2017.

Mike Pollark Analyst — Wolf Research, LLC

So, the data you can add on top, ACEPAS was a post-market study. It's completed, but you still have an open registry that's collecting, or what is the... How are you generating the data that you think?

We have the ability to go back to the original patient population from ACEPAS, the 21,000 that we published, and get the patient outcomes from those that were delivered therapy and who wore the device. And so that is a missing piece of the puzzle right now that we believe if we can add that to the puzzle, then we believe that will be, you know, and obviously if it's positive, then that will be enough to get them to the table.

Mike Pollark Analyst — Wolf Research, LLC

Is that survival data? Oh, shock. So it sounds like close, perhaps not imminent, but I'll remember from another executive, you can. Grow old and have a completed career by the time the guidelines update. So not critical, but would be corroborative and supportive.

I think, you know, there's nothing about the guidelines that is driving our long-range model. You know, we're not building anything into it. We believe this business is going to grow at the top, you know, decile of MedTech without guidelines changes. If guidelines change, then I think you're talking about a different animal, and the growth would really, really get accelerated. But we're not counting on it, but we're certainly working towards it.

Mike Pollark Analyst — Wolf Research, LLC

All right, good. Let's shift gears very much in execution mode, hiring lots of folks, territory creation. Been public for a while, so the awareness is out there, and the performance has been good. Just talk about the hiring environment for what you're looking for today versus, say, last year or the year before that. Maybe the quality of candidates and your process. Has it changed? Are you looking for someone different today than you were looking for two years ago? If so, how?

I think that, you know, we, as we've gotten more experience in the, in the category, I think we've, we've refined what we're looking for. But I don't think it's dramatically changed. We have, we've built our own internal recruiting engine. So we, we do it internally. We have a bunch of really highly capable, highly motivated people that are doing that. I think the market has changed a little bit probably just in the last 12 months given some of the things going on with some of the big cap cardio companies. There's more of those people that are in the funnel now that we hadn't seen as full. And so, you know, I would say we probably have more folks coming from those companies today than we did 12 months ago. And so there's a little bit maybe more concentration around it. The actual recruiting process, we have a really well-defined process that we execute and do a pretty good job of that. But, you know, ultimately recruiting comes down to what territory you're recruiting for, and they're not all created equal. And some of them, you can get a lot of talent in a given territory. Others, it takes a while to find just the right person for that particular scenario. So we feel pretty good about our ability to recruit. You know, we've made a lot of investment in the post-recruitment process, which is, you know, okay, now we've got them on board, and now let's get them trained up, and, you know, we've essentially doubled the amount of time that we take for the training process after we hire them, and we're seeing some really good results from that investment.

Mike Pollark Analyst — Wolf Research, LLC

So the training itself is longer, but for a faster productivity ramp, is that the return? Yeah, yeah. What about? What's been added to the training that wasn't in there before?

I think a lot more scenario planning, territory planning. We've made some really good investments in the data platforms that allow us to do the territory planning, like where are the opportunities in that given territory and how we think about that. And, you know, in the original days, we had this sort of stale Medicare data that we use for prescriber targeting and things like that. Now we have a lot richer data, so that's part of the sales academy training. We also do a lot more scenario role-playing and just getting them ready to deal with the issues that they're going to deal with in the field. And so I think it's a combination, you know, really of all those things. Another example would be we've added in, you know, how to get in the EMR in your accounts. And that was sort of a one-off thing in the early days. But now there's a process that people know exactly how, you know, how to go about that. So there's a number of things like that that we've just really upped our game, and we've seen the benefit of that. We're seeing people, you know, come up that curve more rapidly, and that's what the whole investment was all about.

Mike Pollark Analyst — Wolf Research, LLC

What about your vision for covering the country? Just, you know, how much of it do you think you cover well today? How much of it do you still have to cover? And anything evolving as you balance breadth versus depth of territories based on the last couple years of experience?

Yeah, I think right now we're probably somewhere around 70% coverage. It's a little bit of a tricky metric when you think about it because you can say, okay, I have a rep in this Pica City, you know, in Charlotte, and so I'm covering Charlotte. Well, the competitor may have four reps there, so it's not truly head-to-head in terms of being able to cover it. But I think for us, it's making sure that we are putting reps in the territories where we have good insurance coverage, where we have good indication that there's heavy prescriber concentration, And then I think we're more likely to go deep in accounts and in regions than we are to go wide. There will be time later to go wider, but I think we're going deeper. We're making sure that in the really high producing regions that we've got the resources that we need. And what we're seeing is when we fully resource, we're seeing, you know, the business is really accelerating.

Mike Pollark Analyst — Wolf Research, LLC

Might have been a few calls ago now, there was a mention of sole source, just Kestra. The alternative is no longer, you know, how prevalent is that model? I mean, obviously, it's a good dynamic. It's constructive to hear you winning a situation like that. Was that an outlier? Or do you think there's room for hospitals just using a single vendor for WCD is the future rule? And if so? What are the things you can do to persuade customers to make that choice?

I think it's probably not going to be the majority of situations, and mostly where you'll see opportunities for that will be in the IDN-style organizations where they've got full wound-to-tomb control over it. In the general, like a university hospital or something like that, we're not really contracting with the hospital itself. We're, you know, we're selling to one doc at a time. And so you don't really see that scenario as much because it's also harder to be able to show the full benefit in terms of economic benefit of, you know, quicker discharge from the hospital, fewer readmittance from the hospital. And some of these IDNs are really interested in that kind of data. And they look at our monitoring platform and they say, hey, we can use that data to help us with readmittance and things like that. So I think we'll continue to see some progress in those kind of institutions, but I don't see it as being, you know, the full, hey, we're going to just kind of run across the country doing that. Um, let's shift gears.

Mike Pollark Analyst — Wolf Research, LLC

I want to hit on kind of supply side. The product and capacity, and then I want to hit on revenue cycle, too. Maybe to start on product. You know, you're growing at a very high rate. You're hiring lots of folks. The model is for high rates of growth ahead. You know, there's always that sweet spot of driving fast but not losing control. And, you know, you have a refurbishment kind of element to your solution, and there's a disposable element. You feel good that you can supply all the growth that you're working for? Talk to me about. The supply chain manufacturing side of the equation, and how do you, you know, stay ahead of that curve?

Yeah, I think our ability, especially in these, in the early years, you know, we're a year and a half into this public journey. I think the ability to ramp the business rapidly in this first couple of years will be somewhat governed by the ability to ramp supply chain, because it is so rapid. But we're making investments in all of our, you know, top tier one, tier two suppliers to add additional capacity as we've always planned. But we're making those investments now to make sure that we're capacity is always ahead of the demand. And so in this first couple of years, I think we are somewhat governed by supply, but that's in a controlled way. And so we have a good supply chain that has the ability to ramp. We're actively working that. The big question is always, well, how much capacity do you need and how fast do you need to ramp that? And how do you balance that with, you know, your investments in inventories and CapEx and things like that? And so this is part of the daily navigation that we're doing. But I think each of the suppliers that we have by design has the ability to ramp up quite dramatically so that we will, you know, as we look at the next three, five years, We will have the ability to ramp the business as we add all these salespeople and, you know, continue to add innovation and all that kind of stuff.

Mike Pollark Analyst — Wolf Research, LLC

Revenue cycle. You are a provider. You bill and collect directly, and I forget the number, but there's a lot of payers in the U.S., and it takes time to get to know them and how they'll pay and how they'll ask you questions and so forth. So maybe for the same, you know. Portion of lives in network today. Where is it? Where were you this time last year? And I've always, you know, a portion of the book is on cash accounting. And this, I think if I'm framing it correctly as a function of you're getting to know these payers and your ability to collect from, you know, all that sort of stuff. Eventually, the experience will be sufficient such that you move to accrual and it may turn out in that moment. You know, you can accrue at a higher rate. Where are we in that process? Like, what's just the network coverage today, and how close are we to the entire book being on kind of an accrual method of accounting?

So, to your point, we've made a lot of progress in the last year and a half. If you remember when we went public, we had 67% of our patients were in network. We're in the low 80s now, so really good progress. All of the big headline payers in the U.S., nationals, we're all in network with them, have been in network for a long time, and are now on that process or journey to collect all of that historical collection data, take it to our auditor, and get them converted one at a time into accrual accounting. So we know the playbook. We know the process. It's just a matter of time, so it's just going to happen steadily in the next 12 to 18 months. On the number of payers, there's about 3,200-plus payers in the U.S. Even the incumbent, we know, in that SCAD Protect data that they published out of Germany, they actually mentioned they're 98 percent kind of covered lives, you know, in terms of the national number. But the actual mix of patients that they see is in the low 90s, and it's very typical in most industries to have that five- to six-point delta. It happens for good reason. People are moving between employers, so they're actually changing coverages. There are people that are falling in and out of different plans and things like that. So really for us, the gap to close, Mike, is to go from that low 80s to the low 90s, and we're on our way to do that.

Mike Pollark Analyst — Wolf Research, LLC

Let's shift gears again. Pipeline. There was a mention last call about R&D expense one-timer. Kind of an unusual thing. It was like in the numbers, but you didn't say anything else about it. A project that was to soon be submitted to FDA. Are you at a point where you can say more about what that is and why it's important?

Yeah, the reason we brought that up at the last earnings call was because it was a spike in our R&D expense, and as we said back then, we had an opportunity on a project that we'd been working on for about three years, an internal development project, to accelerate it and get it over the finish line. And so we applied some financial resource to be able to do that. So that's why we brought it up. We're not quite ready to talk about it. I expect we'll be ready before the end of the calendar year to talk about it. So it's imminent. And we're just waiting to the point that we've gotten past the final milestone in terms of submission to the regulatory agencies before we're ready to talk about it. But it's, you know, it's a meaningful. Innovation in our space and a meaningful clinical benefit that will be added to the platform. And it also will give us a real exciting additional platform as we go through time and we continue to innovate into that capability. So it's coming. We'll talk about it soon.

Mike Pollark Analyst — Wolf Research, LLC

I know you're not going to say what it is here. So we'll move on, but I look forward to learning more. Something you can talk about is BioBeat. Kind of another pipeline element. So ambulatory blood pressure monitoring. What's the current vision for that, integrating it into Assure or something standalone? Just talk about the product development roadmap there, and then maybe in parallel, like, if you do something interesting there, how do you get paid for it?

Well, it's another technology that we're very excited about. One of the things that we did when we developed the platform, the Assure platform, was we wanted to make sure that the platform itself was able to... Bring in other technologies, other appliances, if you will, and that we had architected it in such a way that we could do that. Because we knew that our longer-term vision was that this was much more than a shock box. And, you know, that's what the competitive device has always been. And we view this as a high-performance monitor defibrillator that people are going to go home and they're going to wear, and it's going to give patients and clinicians a lot of information about that patient. The first step, the next step, is the non-invasive blood pressure. BioBeat is unique in that they are the only FDA-approved, you know, wireless patch-based non-invasive blood pressure monitor. 70% of the patients in our ACE-PASS data were hypertensive. I can tell you that as we talk to physicians about this technology, they're also very interested in the hypotensive patients, the really slow, really low heart rate patients. And so this is going to give us the ability to help them with both kinds of patients. Our goal is going to be to integrate it into the platform. We don't see it as we're not interested in being a third-party distributor of their product where we're just, you know, throwing their patch-based system into our bag and saying, hey, stick that on and off you go. We're going to integrate it into our platform so that when a patient puts on the platform, and if the physician has selected that as a diagnostic capability that they want, then they will get that, and the patient will automatically have that ability. And that'll be integrated not only in the hardware, but also into the software so that... When the physician pulls up the Kestra care station portal, they'll get not only all the assured data, but they'll also get the non-invasive blood pressure data all integrated in. So that's what the R&D project is all about that we're making good progress on. The two teams are working well together and, you know, just tackling normal kind of R&D project issues, and we're excited about where that goes. It does have its own existing reimbursement code. We're doing a bunch of work trying to figure out how that code will be applied in the way we're going to implement it, because we're going to implement this more as a long-term where, as opposed to the current BioBeat reimbursement is for five to seven days. And so we've got to navigate what that would mean in our situation. But there is an existing code, and we'll be working to make sure that we get some economics coming from that.

Mike Pollark Analyst — Wolf Research, LLC

It sounds like a step on the journey of multivitals. I hear that in this world. 100%. And you already have ECG. Yeah, I'm sure.

And then, well, we, there room on the vest for more. Absolutely. And, and, you know, we've gone to all when you when you get a patient, and that patient is going to wear the device for over three months, and increasingly with these heart failure patients could be four or five months, we've gone to all the work to get them to wear the system. And so our view is, well, if we can figure out how to derive additional clinical utility, then that just makes our product more valuable, and that makes us more likely to be the choice. And so right at the start of a project like this BioBeat project, there is the differentiation capability where a prescriber is going to look at our prescription sheet and say, well, gee, they have a box here for non-invasive blood pressure monitoring, and I see that the competitor doesn't. And I would really like that, and so I'm going to pick these guys. That's at the start. That's before we even talk about any reimbursement and things like that that we may get. So it's the start of a journey towards, you know, having the ability to measure a bunch of different diagnostic qualities of these patients and provide that to these docs so that they can manage them, especially as they're titrating them off of the drug treatments for heart failure.

Mike Pollark Analyst — Wolf Research, LLC

That's a good way to wrap Vision for the Future. Brian and Maseem, thank you for being here.

Okay.

Mike Pollark Analyst — Wolf Research, LLC

Thanks, Mike. Appreciate it.

Analyst Q&A · 1 question
Full-screen source Call document